Theralase(R) Launches Three New Clinical Study Sites in USA
Theralase Technologies has launched three new US-based Clinical Study Sites for its bladder cancer registrational clinical study. The sites include Associated Medical Professionals of NY, Urology of Indiana, and Central Ohio Urology Group. The company's Phase II registration study for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer has enrolled and treated 75 patients to date.
Key clinical results show that 61.9% of patients demonstrated a Complete Response, with Total Response reaching 68.3%. For duration of response, 43.6% of treated patients maintained Complete Response for at least 12 months. The safety profile shows 100% of patients experienced no Serious Adverse Events related to the treatment. According to Kaplan Meier estimates, patients achieving Complete Response have a ≥53.0% chance of remaining cancer-free for 1 year, ≥35.8% for 2 years, and ≥24.9% for 3 years.
Theralase Technologies ha lanciato tre nuovi siti di studio clinico basati negli Stati Uniti per il suo studio clinico di registrazione sul cancro alla vescica. I siti includono Associated Medical Professionals of NY, Urology of Indiana e Central Ohio Urology Group. Lo studio di registrazione di Fase II dell'azienda per il cancro alla vescica non muscolo invasivo resistente al BCG ha arruolato e trattato 75 pazienti fino ad oggi.
I principali risultati clinici mostrano che il 61,9% dei pazienti ha dimostrato una Risposta Completa, con una Risposta Totale che ha raggiunto il 68,3%. Per quanto riguarda la durata della risposta, il 43,6% dei pazienti trattati ha mantenuto una Risposta Completa per almeno 12 mesi. Il profilo di sicurezza mostra che il 100% dei pazienti non ha riportato eventi avversi gravi legati al trattamento. Secondo le stime di Kaplan Meier, i pazienti che ottengono una Risposta Completa hanno una probabilità ≥53,0% di rimanere liberi dal cancro per 1 anno, ≥35,8% per 2 anni e ≥24,9% per 3 anni.
Theralase Technologies ha lanzado tres nuevos sitios de estudio clínico en EE. UU. para su estudio clínico de registro sobre el cáncer de vejiga. Los sitios incluyen Associated Medical Professionals of NY, Urology of Indiana y Central Ohio Urology Group. El estudio de registro de Fase II de la empresa para el cáncer de vejiga no muscular invasivo resistente a BCG ha inscrito y tratado a 75 pacientes hasta la fecha.
Los resultados clínicos clave muestran que el 61.9% de los pacientes demostraron una Respuesta Completa, con una Respuesta Total que alcanzó el 68.3%. En cuanto a la duración de la respuesta, el 43.6% de los pacientes tratados mantuvieron la Respuesta Completa durante al menos 12 meses. El perfil de seguridad muestra que el 100% de los pacientes no experimentaron Eventos Adversos Graves relacionados con el tratamiento. Según las estimaciones de Kaplan Meier, los pacientes que logran una Respuesta Completa tienen una probabilidad ≥53.0% de mantenerse libres de cáncer durante 1 año, ≥35.8% durante 2 años y ≥24.9% durante 3 años.
Theralase Technologies는 방광암 등록 임상 연구를 위한 미국 내 세 곳의 임상 연구 센터를 새로 개설했습니다. 연구 센터는 Associated Medical Professionals of NY, Urology of Indiana, 그리고 Central Ohio Urology Group를 포함합니다. 이 회사의 BCG에 반응하지 않는 비근육 침습성 방광암에 대한 2상 등록 연구에는 지금까지 75명의 환자가 등록되고 치료되었습니다.
주요 임상 결과에 따르면 61.9%의 환자가 완전 반응을 보였으며, 전체 반응률은 68.3%에 달합니다. 반응 지속 시간을 보면 치료받은 환자의 43.6%가 최소 12개월 동안 완전 반응을 유지했습니다. 안전성 프로필은 100%의 환자가 치료와 관련된 심각한 이상 반응이 없음을 보여줍니다. Kaplan-Meier 추정에 따르면, 완전 반응을 달성한 환자는 1년 동안 암이 없는 상태를 유지할 확률이 ≥53.0%, 2년 동안은 ≥35.8%, 3년 동안은 ≥24.9%입니다.
Theralase Technologies a lancé trois nouveaux sites d'études cliniques basés aux États-Unis pour son étude clinique d'enregistrement sur le cancer de la vessie. Les sites comprennent Associated Medical Professionals of NY, Urology of Indiana et Central Ohio Urology Group. L'étude d'enregistrement de Phase II de l'entreprise pour le cancer de la vessie non invasif résistant au BCG a inscrit et traité 75 patients à ce jour.
Les résultats cliniques clés montrent que 61,9 % des patients ont présenté une réponse complète, avec une réponse totale atteignant 68,3 %. En ce qui concerne la durée de la réponse, 43,6 % des patients traités ont maintenu une réponse complète pendant au moins 12 mois. Le profil de sécurité montre que 100 % des patients n'ont présenté aucun événement indésirable grave lié au traitement. Selon les estimations de Kaplan Meier, les patients ayant obtenu une réponse complète ont une probabilité ≥53,0 % de rester sans cancer pendant un an, ≥35,8 % pendant deux ans et ≥24,9 % pendant trois ans.
Theralase Technologies hat drei neue klinische Studienstandorte in den USA für seine registrierende klinische Studie zum Blasenkarzinom eröffnet. Die Standorte umfassen Associated Medical Professionals of NY, Urology of Indiana und Central Ohio Urology Group. Die Phase-II-Registrierungsstudie des Unternehmens für BCG-resistentes, nicht-muskelinvasives Blasenkarzinom hat bisher 75 Patienten eingeschlossen und behandelt.
Wesentliche klinische Ergebnisse zeigen, dass 61,9% der Patienten eine vollständige Ansprechrate zeigten, wobei die Gesamtansprechrate 68,3% erreichte. In Bezug auf die Dauer der Antwort hielten 43,6% der behandelten Patienten ihre vollständige Antwort mindestens 12 Monate lang aufrecht. Das Sicherheitsprofil zeigt, dass 100% der Patienten keine schweren unerwünschten Ereignisse in Verbindung mit der Behandlung erfahren haben. Laut den Kaplan-Meier-Schätzungen haben Patienten, die eine vollständige Antwort erreichen, eine Wahrscheinlichkeit von ≥53,0%, ein Jahr lang krebsfrei zu bleiben, ≥35,8% für zwei Jahre und ≥24,9% für drei Jahre.
- 61.9% of patients showed Complete Response with Total Response reaching 68.3%
- 43.6% of treated patients maintained Complete Response for 12+ months
- 100% safety profile with no Serious Adverse Events
- Expansion to three new US clinical sites, bringing total to 14 in North America
- 15.4% of Complete Response patients maintain cancer-free status at 24 months
- Still in clinical trial phase, pending regulatory approval
- Response rates decline over time (53% at 1 year to 24.9% at 3 years)
- Commercialization not expected until 2026
Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment
TORONTO, ON / ACCESSWIRE / December 9, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has launched three new US-based Clinical Study Sites ("CSSs") for its bladder cancer registrational clinical study; specifically: Associated Medical Professionals of NY (Syracuse, New York), Urology of Indiana (Greenwood, Indiana) and Central Ohio Urology Group (Gahanna, Ohio).
The Principal Investigators ("PIs") for the Theralase® clinical study at the new CSSs are as follows:
Associated Medical Professionals of NY - Ilija Aleksic, MD
Dr. Aleksic graduated summa cum laude from the University at Buffalo and went on to complete medical school at SUNY Upstate Medical University. Dr. Aleksic received his urological surgery training at Albany Medical Center and was a chief resident in 2019. He has also participated in patient advocacy meetings with local and national elected officials. He has published numerous basic science and clinical research with a focus on men's health. He has presented his work at national and international meetings and has won numerous awards.
Urology of Indiana - Eugene Cone, MD
Dr. Cone graduated from Harvard University with High Honors in Biology. He earned an academic scholarship to the Alpert School of Medicine at Brown University, where he obtained his medical degree. He completed his internship in General Surgery and his residency in Urologic Surgery from Duke University in Durham, North Carolina. He then completed a two-year fellowship in urologic oncology in Boston at Massachusetts General Hospital, Brigham and Women's Hospital and Dana Farber Cancer Center.
Central Ohio Urology Group - Benjamin Martin, MD
Dr. Martin is a urologist in Gahanna, Ohio and is affiliated with multiple hospitals in the area, including OhioHealth Grant Medical Center and Mount Carmel St. Ann's Hospital. He received his medical degree from Ohio State University College of Medicine and has been in practice for more than 20 years.
Theralase®'s lead drug, RuvidarTM (TLD-1433), activated by the TLC-3200 Medical Laser System ("TLC-3200") is currently under clinical investigation in Canada and the United States in a Phase II registration study for Bacillus Calmette-Guérin ("BCG")-Unresponsive Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") with or without resected Ta / T1 papillary disease ("Study II").
An estimated 83,190 patients in the United States1 and 12,300 patients in Canada2 will be diagnosed with bladder cancer in 2024. Bladder cancer was the fourth leading cancer in men in 2023, representing
Study II is a Phase 2, single arm, open label clinical study for patients diagnosed with BCG-Unresponsive NMIBC CIS designed in compliance with Health Canada and FDA guidance. The Study Procedure is comprised of the intravesical installation of reconstituted RuvidarTM for 1 hour, followed by TLC-3200 intravesical activation for approximately 1 hour.
To date, Theralase® has enrolled and treated 75 patients in Study II, who have been provided the primary Study Procedure by the CSSs.
For the primary endpoint of Study II (Complete Response3 ("CR") at any point in time)
Including patients, who demonstrated an Indeterminate Response4 ("IR") to the CR number, the Total Response ("TR") increased to
Performance to Primary Objective:
| Primary Endpoint Performance (CR at any Point in Time) | ||
# | % | Confidence Interval ( | |
Complete Response ("CR") | 39 | [42.5, 81.3] | |
Total Response (CR and IR) | 43 | [47.9, 88.7] |
Performance to Secondary Objective:
For the secondary endpoint of Study II (duration of CR)
| Secondary Endpoint Performance (Duration of CR) (450 Days) | ||
| # | % | Confidence Interval ( |
Complete Response ("CR") | 17 | [22.9, 64.3] |
Performance to Tertiary Objective:
For the tertiary endpoint of Study II (safety of Study Procedure)
| Tertiary Endpoint Performance (Safety) (450 Days) | |
| # | % |
Safety | 63 |
In addition,
According to a Kaplan Meier Curve estimate, if CR is obtained, then the patient has a ≥
The total clinical study sites enrolling patients in North America is now 14 (6 in Canada, 8 in US) with an additional CSS scheduled to launch in 1Q2025.
Christopher Pieczonka, MD, Chief Executive Officer of Associated Medical Professionals of NY, stated, "Our clinical team isextremely interested in the clinical investigation of Theralase®'s drug-device technology; specifically, light-activated Ruvidar™, for the treatment of patients diagnosed with BCG-Unresponsive NMIBC CIS. Based on the clinical data collected to date, this technology, if approved by the FDA, represents a great alternative for patients who wish to have the opportunity of having their bladder cancer treated safely and effectively, while preserving their quality of life, versus undergoing a radical cystectomy (bladder removal surgery). I am impressed by Theralase®'s clinical data, which has demonstrated a strong patient efficacy response, duration of that response up to ≥ 3 years with a single treatment and a strong safety profile. I look forward to working with Theralase® and our clinicians to launch this clinical study at our various locations and in the enrollment and treatment of patients."
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer of Theralase® stated, "I am pleased that Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group have agreed to become clinical study sites to participate in this exciting clinical study research. I welcome Dr. Aleksic, Dr. Cone and Dr. Martin to the esteemed team of the Study II Principal Investigators, who are currently working to complete this clinical study and help Theralase® prepare for Health Canada and FDA regulatory approval in 2026. Theralase® is focused on expediting the development of the Theralase ® technology, which is showing an opportunity for BCG-Unresponsive NMIBC CIS patients to maintain their quality of life, through retention of their bladders for ≥ 3 years, after a single Study Procedure. Our hope is that the clinical data generated from this study will support the commercialization of Ruvidar and our mandate of optimizing bladder cancer care by delivering state-of-the-art technology that significantly improves patient outcomes."
Roger DuMoulin-White, B.E.Sc., P.Eng., Pro.Dir., President and Chief Executive Officer of Theralase® stated, "I am delighted that Dr. Aleksic, Dr. Cone and Dr. Martin and their respective teams at Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group have agreed to participate in Study II. Theralase® looks forward to working with them and the other principal investigators in Canada and the United States to successfully complete Study II and commercialize this revolutionary technology internationally for the benefit of all patients diagnosed with this disease.As Theralase® completes enrollment in its clinical study, in 2025, Theralase® is actively seeking partnering / licensing opportunities for various geographical territories around the world in the commercialization of Ruvidar™ for the treatment of BCG-Unresponsive NMIBC."
1Key Statistics for Bladder Cancer | American Cancer Society (2024)
2Bladder cancer statistics | Canadian Cancer Society (2024)
3 Complete Response ("CR") is defined as negative cystoscopy and negative urine cytology; positive cystoscopy (low grade) and negative cytology or negative cystoscopy and suspicious / positive urine cytology with confirmed upper tract / prostatic urethra disease and negative bladder biopsies
4 Indeterminate Response ("IR") is defined as negative cystoscopy and positive urine cytology, without confirmatory negative bladder biopsies
About Theralase® Technologies Inc.:
Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedarplus.ca
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include; but, are not limited to statements regarding the Company's proposed development plans with respect to small molecules and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management regarding future research, development and commercialization of the Company's small molecules; their drug formulations; preclinical research; clinical studies and regulatory approvals.
These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to fund and secure the regulatory approvals to successfully complete various clinical studies in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its small molecule and drug formulations; the risk that access to sufficient capital to fund the Company's operations may not be available on terms that are commercially favorable to the Company or at all; the risk that the Company's small molecule and drug formulations may not be effective against the diseases tested in its clinical studies; the risk that the Company's fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business; the Company's ability to protect its intellectual property; the timing and success of submission; acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.
Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will prove to be accurate as such FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.
Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.
All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such FLS.
For investor information on the Company, please feel to reach out Investor Inquiries - Theralase Technologies.
For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com
Kristina Hachey, CPA
Chief Financial Officer X 224
khachey@theralase.com
SOURCE: Theralase Technologies, Inc.
View the original press release on accesswire.com
FAQ
What are the latest clinical trial results for Theralase (TLTFF) bladder cancer treatment?
How many clinical study sites does Theralase (TLTFF) now have for its bladder cancer treatment?
When does Theralase (TLTFF) expect regulatory approval for its bladder cancer treatment?